Erasca, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Erasca, Inc. (ERAS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $9.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $9.61M, a 50.14% increase year-over-year.
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.46M, a 26.02% increase year-over-year.
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.96M, a 10.13% decline year-over-year.
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.40M, a 10.89% decline year-over-year.
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $24.90M, a 7.69% decline from fiscal 2024.
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $26.97M, a 2.83% increase from fiscal 2023.
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $26.23M, a 30.44% increase from fiscal 2022.
- Erasca, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $20.11M, a 141.38% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.61M 10-Q · filed 2026-08-11 | $18.07M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $8.46M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $24.90M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $5.96M 10-Q · filed 2025-11-12 | $12.36M derived: sum of 2 quarters · filed 2026-08-11 | $19.08M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $6.40M 10-Q · filed 2026-08-11 | $13.11M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $6.71M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $26.97M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $6.64M 10-Q · filed 2025-11-12 | $13.82M derived: sum of 2 quarters · filed 2025-11-12 | $20.66M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $7.18M 10-Q · filed 2025-11-12 | $14.03M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $6.85M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $26.23M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $6.24M 10-Q · filed 2024-11-12 | $13.25M derived: sum of 2 quarters · filed 2024-11-12 | $20.09M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $7.01M 10-Q · filed 2024-11-12 | $13.86M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $6.84M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $20.11M 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $5.23M 10-Q · filed 2023-11-09 | $10.29M derived: sum of 2 quarters · filed 2023-11-09 | $14.73M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $5.05M 10-Q · filed 2023-11-09 | $9.50M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $4.44M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $8.33M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $3.02M 10-Q · filed 2022-11-09 | $4.65M derived: sum of 2 quarters · filed 2022-11-09 | $5.45M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.64M 10-Q · filed 2022-11-09 | $2.43M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $795.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $797.00K 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $176.00K 10-Q · filed 2021-11-10 | $285.00K derived: sum of 2 quarters · filed 2021-11-10 | $390.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $109.00K 10-Q · filed 2021-11-10 | $214.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $105.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |